Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
MD

NASDAQ · MDCXW

Medicus Pharma Ltd.

Healthcare · Biotechnology

$0.32

Down-$0.01 (-3.61%)

Updated Sep 19, 2026, 4:51 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
22.92M
P/E ratio
-2.65
Dividend yield
0.00%
52-week range
$0.20 – $1.45
Volume
863.51
Avg. volume
6.01K

Price performance

MDCXW price history

1M range · 7 trading sessions · Daily adjusted prices

MDCXW closed at $0.32 after 7 trading sessions, down 17.09% for the selected period.

Last close
$0.32
Period change
-17.09%
Period low
$0.31
Period high
$0.40
Daily close
View OHLC price history
MDCXW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$0.44$0.44$0.3216$0.3216863.51
Sep 10, 2026$0.39$0.39$0.31$0.31906.4
Sep 9, 2026$0.46$0.46$0.40$0.40217
Sep 4, 2026$0.31$0.3101$0.31$0.3101228
Sep 3, 2026$0.31$0.35$0.31$0.332.69K
Sep 2, 2026$0.32$0.32$0.30$0.312.97K
Aug 31, 2026$0.3879$0.3879$0.3879$0.3879226.2

Latest MDCXW news

The latest Smart Investors Daily articles mentioning MDCXW.

Stock researchCompany · Overview

MDCXW research

Overview

Company profile and research snapshot.

Company profile

Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

What Is Pfizer (PFE) Really Getting From Its New ADC Licensing Deal?

Pfizer (NYSE:PFE) has signed a co-development and license deal with Medicus Pharma for an early clinical-stage CD228-targeting antibody-drug conjugate. The agreement grants Medicus exclusive global rights to develop and commercialize the CD228V candidate across multiple human disease areas. Pfizer retains economic participation through financial milestones, royalties and ongoing involvement in the CD228V development program. This new Pfizer Medicus CD228V antibody-drug conjugate partnership...

Yahoo · Sep 12, 2026

Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI

Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical, partnership and funding developments as the company sharpens its focus on precision oncology and...

Yahoo · Sep 10, 2026

Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss a transformative agreement with Pfizer that significantly strengthens the company’s position in precision oncology and provides key resources to advance its lead cancer program. Under the development and licensing agreement, Medicus has secured rights to a CD228-targeted antibody-drug conjugate (ADC) program, while Pfizer is contributing approximately $2 million in development funding, along with inventory and infrastructure support. Bokhari described the transaction as a major milestone that effectively provides the company with the resources needed to continue development from where Pfizer concluded its Phase 1 dose-escalation work. The CD228-targeted ADC is being developed for the treatment of solid tumors, including refractory melanoma, and now represents the centerpiece of Medicus’ evolving oncology strategy. Bokhari said the agreement allows the company to move forward with a capital-efficient approach while leveraging the extensive scientific and clinical groundwork already completed by Pfizer. Beyond oncology, Medicus continues to make progress with its SkinJect program, which is focused on the treatment of basal cell carcinoma and related conditions. Bokhari noted that final clinical trial results recently published on ClinicalTrials.gov identified the 200-microgram patch as the optimal dose for future registrational studies. The company is now concentrating its efforts on advancing SkinJect in patients with Gorlin syndrome, a rare genetic condition that can lead to the development of multiple basal cell carcinomas throughout a patient’s lifetime. Medicus is preparing to move forward with the FDA-approved pivotal SkinJect 005 study while simultaneously recruiting patients for the trial. At the same time, Bokhari said the company is positioning the broader nodular basal cell carcinoma opportunity for potential out-licensing, allowing Medicus to focus internal resources on the areas where it sees the strongest risk-adjusted return. To support the commercial potential of SkinJect, Medicus commissioned an independent reimbursement analysis that suggests the treatment could potentially achieve reimbursement levels of $25,000 or more per patient. Bokhari noted that the rare disease and potential pediatric disease characteristics associated with Gorlin syndrome could provide attractive regulatory and commercial advantages. He described SkinJect as “partner-ready” and indicated that the company is actively exploring opportunities to unlock additional value through strategic partnerships. Bokhari characterized the Pfizer agreement as a paradigm shift for Medicus, transforming the company into a precision oncology-focused biotechnology business while maintaining a disciplined approach to capital allocation. He compared the strategy to a Berkshire Hathaway-style model for drug development, where resources are selectively deployed into programs with the highest potential returns. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #Pfizer #PrecisionOncology #Biotech #CancerResearch #ADC #Melanoma #DrugDevelopment #ClinicalTrials #SkinJect #GorlinSyndrome #Biotechnology #HealthcareInnovation #Oncology #LifeSciences

Yahoo · Sep 10, 2026

Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study

The completed SKNJCT-003 study is shaping Medicus Pharma’s next clinical strategy, with the 200 µg dose moving into an FDA-authorized Gorlin syndrome program while the company considers partnerships for nodular basal cell carcinoma. Key Investor TakeawaysMedicus Pharma (NASDAQ:MDCX) selected the 200 µg SkinJect patch as its proposed pivotal dose following the final analysis of its 90-patient Phase 2 SKNJCT-003 study.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By